Clinical trials: Radiotherapy-Induced Immune Priming
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Radiotherapy-Induced Immune Priming
Spatially Fractionated Radiotherapy for Tumor Treatment
To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.
- Trial name
- NCT07774819
- Testing
- spatially fractionated radiotherapy
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Xu Zhi-yuan
Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming
Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study
The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer.
- Conditions
- Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response
- Trial name
- TRIUNITE-07 (NCT07467590)
- Testing
- High- and Low-Dose Radiotherapy, Anti-Angiogenic TKI and Anti-PD-1 Therapy
- Volunteers
- 33 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University